Telomere Biomarker Blood Test Predicts Cancer Years In Advance
By LabMedica International staff writers Posted on 12 May 2015 |
Image: Telomeres at the end of the chromosomes protecting against DNA deterioration (Photo courtesy of Dr. Joseph Raffaele, MD).
Telomeres are sequences of DNA on the ends of chromosomes that stop them fraying and losing their integrity, but they gradually shorten as one ages and by the time one grow up they are half the length they were when a person was born, then they halve again as they enter old age.
Telomeres shorten every time a cell divides, which is why they get progressively shorter as they age and if the telomeres of a cell become too short, they can cause the cell to become faulty, and normally the cell self-destructs. However since cancer cells divide more rapidly than normal cells, the question arises why they do not self-destruct when their telomeres become dangerously short.
Scientists at Northwestern University Feinberg School of Medicine (Chicago, IL, USA) measured telomere length several times over a 13-year period in 792 people. One hundred and thirty-five of the participants eventually developed various cancers, including leukemia, and prostate, skin and lung cancer. The telomeres of the participants who were later diagnosed with cancer aged much faster, that is they shortened more rapidly, in the first few years. In the participants who developed cancer, the telomeres looked as much as 15 years older than those of the participants who did not develop cancer. But what was surprising was that the accelerated aging stopped three to four years before cancer diagnosis.
The authors concluded that relative to approaching cancer diagnosis, age-adjusted blood telomere length (BTL) attrition decelerated in cancer cases, ultimately yielding significantly elongated BTL and suggesting that critical BTL shortening may contribute to cancer initiation which then, in turn, activates telomere maintenance mechanisms to compensate and further promote cancer. These results may help explain the inconsistent results of previous studies and provide more insight into using BTL as an early detection biomarker of cancer.
Lifang Hou, MD, PhD, the lead study author, said, “Understanding this pattern of telomere growth may mean it can be a predictive biomarker for cancer. Because we saw a strong relationship in the pattern across a wide variety of cancers, with the right testing these procedures could be used to eventually diagnose a wide variety of cancers.” The study was published online on the April 30, 2015, in the journal EbioMedicine.
Related Links:
Northwestern University Feinberg School of Medicine
Telomeres shorten every time a cell divides, which is why they get progressively shorter as they age and if the telomeres of a cell become too short, they can cause the cell to become faulty, and normally the cell self-destructs. However since cancer cells divide more rapidly than normal cells, the question arises why they do not self-destruct when their telomeres become dangerously short.
Scientists at Northwestern University Feinberg School of Medicine (Chicago, IL, USA) measured telomere length several times over a 13-year period in 792 people. One hundred and thirty-five of the participants eventually developed various cancers, including leukemia, and prostate, skin and lung cancer. The telomeres of the participants who were later diagnosed with cancer aged much faster, that is they shortened more rapidly, in the first few years. In the participants who developed cancer, the telomeres looked as much as 15 years older than those of the participants who did not develop cancer. But what was surprising was that the accelerated aging stopped three to four years before cancer diagnosis.
The authors concluded that relative to approaching cancer diagnosis, age-adjusted blood telomere length (BTL) attrition decelerated in cancer cases, ultimately yielding significantly elongated BTL and suggesting that critical BTL shortening may contribute to cancer initiation which then, in turn, activates telomere maintenance mechanisms to compensate and further promote cancer. These results may help explain the inconsistent results of previous studies and provide more insight into using BTL as an early detection biomarker of cancer.
Lifang Hou, MD, PhD, the lead study author, said, “Understanding this pattern of telomere growth may mean it can be a predictive biomarker for cancer. Because we saw a strong relationship in the pattern across a wide variety of cancers, with the right testing these procedures could be used to eventually diagnose a wide variety of cancers.” The study was published online on the April 30, 2015, in the journal EbioMedicine.
Related Links:
Northwestern University Feinberg School of Medicine
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans